Wikisage, the free encyclopedia of the second generation, is digital heritage
Diacomit: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
Diacomit contains 250 mg stiripentol<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf</ref> | Diacomit contains 250 mg stiripentol<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf</ref> | ||
<gallery>File:(±)-Stiripentol Structural Formulae V.1.svg.png</gallery> | <gallery>File:(±)-Stiripentol Structural Formulae V.1.svg.png</gallery> | ||
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union | |||
Dravet Syndrome does not exist data | Dravet Syndrome does not exist data | ||
==atc== | ==atc== | ||
Revision as of 18:51, 31 March 2016
Diacomit contains 250 mg stiripentol[1]
-Stiripentol_Structural_Formulae_V.1.svg.png)
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
Dravet Syndrome does not exist data